BHT-3034

DB18045ExperimentalVaccines

BHT-3034 is a DNA plasmid vaccine immunotherapy under investigation for the treatment of myasthenia gravis.

Code names
BHT-3034

What you can answer from here — as of April 02, 2025

1+ReferenceStructured and connected to the statements they support
Sign in

Which companies are running trials of BHT-3034, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In